UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  January 23, 2009

 

DEPOMED, INC.

(Exact name of registrant as specified in its charter)

 

001-13111

(Commission File Number)

 

 

1360 O’Brien Drive, Menlo Park, California  94025

(Address of principal executive offices, with zip code)

 

(650) 462-5900

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

On January 23, 2009, the compensation committee of the board of directors of Depomed, Inc. (the “Company”) approved 2009 base salaries for the Company’s executive officers, and approved the payment of 2008 bonuses to executive officers pursuant to the Company’s bonus plan.  Also on January 23, 2009, the compensation committee approved grants to the Company’s executive officers to purchase the Company’s common stock pursuant to the Company’s 2004 Equity Incentive Plan.  The exercise price for each stock option is $1.83 per share, which is equal to the closing price of the Company’s common stock on the date of grant.  The stock options vest in equal monthly installments over 48 months from the date of grant.

 

The 2008 bonus payments, 2009 base salaries and the stock option grants are set forth in the table below.

 

Officer		Bonus Amount ($)		2009 Base Salary ($)		Stock Options (#)
Carl A. Pelzel President and Chief Executive Officer		275,000		450,000		200,000
Tammy L. Cameron Vice President, Finance		80,000		207,000		65,000
Matthew M. Gosling Vice President and General Counsel		124,000		340,000		70,000
Michael Sweeney, M.D. Vice President, Research and Development		130,000		328,000		85,000

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

	DEPOMED, INC.
Date: January 27, 2009		/s/ Matthew M. Gosling
		Matthew M. Gosling
		Vice President and General Counsel

 

3